Медицинская литература. Новинки

 

 

 

 

 

 

Диагностика и лечение гастринпродуцирующих опухолей желудочно-кишечного тракта

Вы можете загрузить полный текст статьи в формате pdf

Обзор отечественной и зарубежной литературы посвящен диагностике гастринпродуцирующих опухолей желудочнокишечного тракта и методам их комплексного лечения. Представлены данные об эпидемиологии гастрином, клинической картине синдрома Золлингера–Эллисона. Показаны трудности проведения синдромальной и топической диагностики данного заболевания. Проведена сравнительная оценка таких методов диагностики, как УЗИ, КТ, МРТ, ССР, эндо-УЗИ, селективная ангиография, ЧЧЗКВ, и АСЗК с последующим определением уровня гастрина в пробах крови. Авторами показаны основные направления в лечении гастрином: подавление кислотпродуцирующей функции желудка и удаление самой опухоли, а также ее метастазов. При невозможности выполнения радикального оперативного вмешательства комплексную терапию необходимо дополнять специфической химио-, иммуно- и биотерапией.

Ключевые слова:
гастринома, синдром Золлингера–Эллисона, клиника, диагностика, лечение.

Литература:
1. Егоров А.В., Кузин Н.М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы // Практ. онкол.
2005. Т. 6. №4. С. 206–212.
2. Горбунова В.А, Орел Н.Ф., Егоров Г.Н. Высокодифференцированные нейроэндокринные опухоли (карциноиды) и
нейроэндокринные опухоли поджелудочной железы. Современный взгляд на проблему. М.: Литтерра, 2007.
3. Гуревич Л.Е. Диагностика нейроэндокринных опухолей желудочно-кишечного тракта // Практ. онкол. Т. 6. №4. 2005.
4. Кузин Н.М., Егоров А.В. Нейроэндокринные опухоли поджелудочной железы. Руководство. М.: Медицина, 2001.
5. Черноусов А.Ф., Егоров А.В., Кондрашин С.А. Диагностика и лечение гастринпродуцирующих опухолей и синдрома Золлингера–Эллисона // Вест. хир. гастроэнтерол. 2007. №3. С. 17–26.
6. Anderson M.A., Carpenter S., Thompson N.W. et al. Endoscopic
ultrasound is highly accurate and directs management in
patients with neuroendocrine tumors of the pancreas // Am. J.
Gastroenterol. 2000. V. 95. P. 2271–2277
7. Anlauf M., Garbrecht N., Henopp T. et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: Distinct clinicopathological and epidemiological features // Wld J.
Gastroenterol. 2006. V. 14. N12(34). P. 5440–5446.
8. Arnold C. Neuroendocrine tumors of the gastrointestinal tract //
Schweiz. Rundsch Med. Prax. 2007. V. 96(1–2). P. 19–28.
9. Arnold R. Diagnosis and differential diagnosis of hypergastrinemia // Wien Clin. Wochenschr. 2007. V. 119(19–20). P. 564–569.
10. Auernhammer C.J, Göke B. Medical treatment of gastrinomas //
Wien Clin. Wochenschr. 2007. V. 119(19–20). P. 609–615.
11. Azoulay D., Bismuth H. Role of liver surgery and transplantation
in patients with hepatic metastases from pancreatic endocrine
tumors / Ed. Mignon M., Jensen R.T. Endocrine tumors of the
pancreas: Recent advances in research and management. New
York: Karger, 1995. P. 461–476
12. Cisco R.M., Norton J.A. Surgery for gastrinoma // Adv. Surg.
2007. V. 41. P. 165–176.
13. Dadan J., Wojskowicz P., Wojskowicz A. Neuroendocrine tumors
of the pancreas // Wiad. Lek. 2008. V. 61(1–3). P. 43–47.
14. Davì M.V., Bodei L., Ferdeghini M. et al. Multidisciplinary
approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177LuDOTATATE ([177Lu-DOTA0, Tyr3]octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal // Endocrin. Pract. 2008. V. 14(2). P. 213–238.
15. Dolan J.P, Norton J.A. Essential Practice of Surgery Basic
Science and Clinical Evidence Neuroendocrine Tumors of the
Pancreas and Gastrointestinal Tract and Carcinoid Disease. New
York: SpringerVerlag, 2003.
16. Ellison E.C., Johnson J.A. The ZollingerEllison syndrome:
a comprehensive review of historical, scientific, and clinical
considerations // Curr. Probl. Surg. 2009. V. 46(1). P. 13–106.
17. Faggiano A., Mansueto G., Ferolla P. Diagnostic and prognostic
implications of the World Health Organization classification of
neuroendocrine tumors // J. Endocrinol. Invest. 2008. V. 31(3).
P. 216–223.
18. Falconi M., Bettini R. et al. Surgical Strategy in the Treatment of
Pancreatic Neuroendocrine Tumors JOP // J. Pancr. 2006.
V. 7(Suppl. 1). P. 150–156.
19. Gibril F., Reynolds J.C., Chen C.C. et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of
falsepositive localizations on management in patients with gastrinomas // J. Nucl. Med. 1999. V. 40. N 4. P. 539–553.
20. Gibril F., Schumann M., Pace A., Jensen R.T. Multiple endocrine
neoplasia type 1 and ZollingerEllison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature // Med. 2004. V. 83. P. 43–83.
21. Granberg D., Jacobsson H., Oberg K. et al. Regression of a large
malignant gastrinoma on treatment with Sandostatin LAR:
a case report // Digestion. 2008. V. 77(2). P. 92–95.
22. Gupta S. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival //
Canc. 2005. V. 104. P. 1590–1602.
23. Hansen C.P., Knigge U. Biotherapy of neuroendocrine tumours
of the gastrointestinal tract and pancreas // Ugeskr. Laeger. 2008.
V. 9. N 170(24). P. 2145–2148.
24. Happel B., Niederle B., Puespoek A., Ba#Ssalamah A. et al.
Benign neuroendocrine and other rare benign tumors of the pancreas // Radiol. 2008. V. 48(8). P. 752–763.
25. Jeffrey A. Norton, MD Essential Practice of Surgery: Basic
Science and Clinical Evidence. New York: SpringerVerlag, 2003.
26. Jensen R., Niederle B., Mitry E., Ramage J.K. Gastrinoma (duodenal and pancreatic) // Neuroendocrinol. 2006. V. 84.
P. 173–182.
27. Kann P.H. The value of endoscopic ultrasound in localizing gastrinoma // Wien. Clin. Wochenschr. 2007. V. 119(19–20).
P. 585–587.
28. Klose K.J., Heverhagen J.T. Localisation and staging of gastrin
producing tumours using crosssectional imaging modalities //
Wien Clin. Wochenschr. 2007. V. 119(19–20). P. 588–592.
29. Komminoth P., Perren A., Oberg K. et al. Pathology and Genetics:
Tumors of the Endocrine Organs. WHO classification of
tumors / Gastrinoma: in DeLellis R.A., Lloyd R., Heitz P.U. et
al. Lyon: IARC Press, 2004. P. 191–194.
30. Kwekkeboom D.J., Bakker W.H., Kam B.L. et al. Treatment of
patients with Gastroenteropancreatic (GEP) tumours with the
novel radiolabelled somatostatin analogue [177 LuDOTA?, Tyr3]
octreotate [abstract] // Eur. J. Nucl. Med. Mol. Imag. 2003.
V. 30. P. 417–422.
31. Lorenz K., Dralle H. Surgical treatment of sporadic gastrinoma //
Wien Clin. Wochenschr. 2007. V. 119(19–20). P. 597–660.
32. Maton P.N., Miller D.L., Doppman J.L. et al. Role of selective
angiography in the management of patients with ZollingerEllison syndrome // Gastroenterol. 1987. V. 92. P. 913–918.
33. Modlin I.M., Oberg K., Chung D.C. et al. Gastroenteropancreatic
neuroendocrine tumours // Lancet. Oncol. 2008. V. 9(1). P. 61–72.
34. Norton J.A., Jensen R.T. Current surgical management of
ZollingerEllison syndrome (ZES) in patients without multiple
endocrine neoplasiatype 1 (MEN1) // Surg. Oncol. 2003. V. 12.
P. 145–151
35. Oberg K., Kvols L., Caplin M. et al. Consensus report on the use
of somatostatin analogs for the management of neuroendocrine
tumors of the gastroenteropancreatic system // Ann. Oncol.
2004. V. 15. P. 966–973.
36. Pansky B. Anatomy of the pancreas // Int. J. Pancreatol. 1990.
V. 101. P. 108.
37. Prasad V., Fetscher S., Baum R.P. Changing role of somatostatin
receptor targeted drugs in NET: nuclear medicine’s view //
J. Pharm. Pharmaceut Sci (www. cspsCanada.org). 2007.
P. 321–337.
38. Rambaldi P.F., Cuccurullo V., Briganti V. et al. The present and
future role of In 111 Pentetreotide in the PET era // Q. J. Nucl.
Med. Mol. Imag. 2005. V. 49. P. 225–235.
39. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut
(neuro)endocrine tumors: a consensus proposal including a
grading system // Virchows Arch. 2006. V. 449. P. 395–401.
40. Ruiz#Tovar J., Priego P., Martínez#Molina E. et al. Pancreatic
neuroendocrine tumours // Clin. Transl. Oncol. 2008. V. 10(8).
P. 493–497.
41. Schwart A., Pertsemlidis D., Gagner M. Endocrine Surgery. New
York: Marcel Dekker, 2004.
42. Shibata C., Funayama Y., Fukushima K. et al. Role of selective
arterial secretin injection test in treatment of gastrinoma //
Hepatogastroenterol. 2006. V. 53(72). P. 960–963.
43. Shojamanesh H., Gibril F., Louie A. et al. Prospective study of the
antitumor efficacy of longterm octreotide treatment in patients
with progressive metastatic gastrinoma // Canc. 2002. V. 94.
P. 331–343.
44. Stabile B.E., Passaro E.Jr. Benign and malignant gastrinoma //
Am. J. Surg. 1985. V. 149. P. 144–150.
45. Strosberg J., Hoffe S., Gardner N. et al. Effective treatment of
locally advanced endocrine tumors of the pancreas with
chemoradiotherapy // Neuroendocrinol. 2007. V. 85 (4).
P. 216–236
46. Thompson N.W., Pasieka J., Fukuuchi A. Duodenal gastrinomas,
duodenotomy, and duodenal exploration in the surgical management of Zollinger–Ellison syndrome // World J. Surg. 1993.
V. 17. P. 455–462.
47. Thomson A.B. Are the orally administered proton pump
inhibitors equivalent? a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole // Curr. Gastroenterol. Rep.
2000. V. 2. P. 482–493
48. Tomassetti P., Campana D., Piscitelli L. et al. Treatment of
ZollingerEllison syndrome // World J. Gastroenterol. 2005.
V. 11(35). P. 5423–5432.
49. Zatelli M.C., Torta M., Leon A. et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Endocr Relat Canc. 2007. V. 14(2). P. 473–82.
50. Zollinger R.M., Ellison E.H. Primary peptic ulcerations of the
jejunum associated with islet cell tumors of the pancreas // Canc.
J. Clin. 1989. V. 39. P. 231–247.
51. Zollinger R.M. Gastrinoma: the ZollingerEllison syndrome //
Semin. Oncol. 1987. V. 14. P. 247–252.

Diagnostic and treatment gastrine – producing tumors of gastrointestinal tract

The authors review the problems of diagnostic and complex treatment of gastrinproducing tumors of the gastrointestinal tract. Epidemiology, clinical signs and problems of syndrome and topical diagnose of ZES are discussed. The following diagnostic procedures as US, CT, MRI, SRS, EUS, selective angiography and arterial stimulated blood sampling are compared. The basic directions in treatment of gastrinomes are shown: suppression of acid producing function of a stomach and resection of the leasion and its metastasises. In case of unresectable tumor specific chemo, immuno and biotherapy is indicated.

Keywords:
gastrinoma, Zollinger#Ellison syndrom, diagnostics, clinic, treatment.